Related Experiment Videos
Novel costimulators in the immune gene therapy of cancer
J Galea-Lauri1, F Farzaneh, J Gäken
1Department of Molecular Medicine, King's College School of Medicine and Dentistry, Rayne Institute, London, England.
Abstract:
One of the major goals of cancer immunotherapy is the induction of tumour-specific T-lymphocyte responses that will be effective in the rejection of established tumours. The prospects for such therapy rely on the identification of tumour antigens, and although there is persuasive evidence for the presence of such antigens,1,2 the occurrence of the disease does illustrate that the immune system is at least, on some occasions, unable to recognise and destroy these targets. Tumour antigens may be novel proteins (from genetic lesions or viral infections), modified existing antigens (eg, abnormally glycosylated cell surface proteins), or inappropriately expressed normal gene products (eg, CA125, carcinoembryonic antigen, and alpha-fetoprotein).1 Involvement of the immune system in the normal surveillance and suppression of cancer is further suggested by the increased incidence of tumours in immunocompromised patients.3 However, recent evidence has shown that, at least in model systems, cancer cells can be modulated in such a way that they stimulate cells of the immune system to recognise and destroy these malignant cells. This review summarizes the costimulatory molecules involved in the activation of such cells, the principles and mechanisms underlying their activation, and how such knowledge can be used to persuade the immune system to challenge cancer.
Insights
Cancer immunotherapy aims to activate T-lymphocytes against tumors by identifying tumor antigens. This review explores costimulatory molecules and mechanisms to enhance immune responses against cancer.
Area of Science:
- Immunology
- Oncology
- Biochemistry
Background:
- Cancer immunotherapy seeks to induce tumor-specific T-lymphocyte responses for tumor rejection.
- Tumor antigens, including novel proteins, modified existing antigens, or inappropriately expressed normal gene products, are crucial for immune recognition.
- The increased incidence of tumors in immunocompromised patients highlights the immune system's role in cancer surveillance.
Purpose of the Study:
- To review costimulatory molecules involved in immune cell activation for cancer immunotherapy.
- To summarize the principles and mechanisms underlying immune cell activation against cancer.
- To explore how this knowledge can be applied to enhance the immune system's ability to target cancer cells.
Main Methods:
- Literature review of studies on cancer immunotherapy, tumor antigens, and immune cell activation.
- Analysis of mechanisms involving costimulatory molecules in immune responses.
- Synthesis of current knowledge on modulating cancer cells to stimulate immune recognition and destruction.
Main Results:
- Identification of various types of tumor antigens (novel, modified, inappropriately expressed).
- Understanding the role of costimulatory molecules in T-lymphocyte activation.
- Evidence from model systems suggests cancer cells can be modulated to stimulate immune destruction.
Conclusions:
- Effective cancer immunotherapy relies on identifying tumor antigens and understanding immune activation pathways.
- Costimulatory molecules play a critical role in orchestrating anti-tumor immune responses.
- Modulating cancer cells and leveraging costimulatory pathways offers a promising strategy to enhance cancer immunotherapy.